Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isoquercetin in Sickle Cell Disease
NCT04474626Phase 2Withdrawn
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of isoquercetin in sickle cell disease (SCD). Planned start Dec 2020; status: withdrawn.
02
Drugs
isoquercetin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04474626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04474626.